Clinical Trial Update: Lonafarnib, Trastuzumab, and Paclitaxel in Treating Patients With HER2/Neu-Overexpressing Stage IIIB, Stage IIIC, or Stage IV Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the combination of lonafarnib, trastuzumab, and paclitaxel in HER2-overexpressing stage IIIB/IIIC or stage IV breast cancer; the study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Lonafarnib (lonafarnib)
• PACLITAXEL (PACLITAXEL)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC | Conditions: Breast Cancer | Phase 1 | Status: COMPLETED